Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 373; číslo 23; s. 2247 - 2257
Hlavní autori:	Pfeffer, Marc A, Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C, Køber, Lars V, Lawson, Francesca C, Ping, Lin, Wei, Xiaodan, Lewis, Eldrin F, Maggioni, Aldo P, McMurray, John J.V, Probstfield, Jeffrey L, Riddle, Matthew C, Solomon, Scott D, Tardif, Jean-Claude
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 03.12.2015
Predmet:	Acute Coronary Syndrome - complications Acute Coronary Syndrome - drug therapy Acute coronary syndromes Aged Angina Angina, Unstable - complications Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cerebral infarction Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Drug dosages Drug therapy Female GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Glucose Glycated Hemoglobin A - analysis Heart diseases Heart failure Heart rate Hemoglobin Humans Hypersensitivity Hypoglycemia Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Kaplan-Meier Estimate Male Middle Aged Morbidity Mortality Myocardial infarction Myocardial Infarction - complications Pancreas Pancreatic cancer Pancreatitis Peptides - adverse effects Peptides - therapeutic use Proportional Hazards Models Regulatory approval Treatment Failure
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events. Randomized trials involving patients with new or established type 2 diabetes have shown that improved glucose control reduces the risk of microvascular complications, 1 – 3 with modest cardiovascular benefits suggested by meta-analyses and extended follow-up of clinical trials. 4 – 7 However, various studies indicate that, despite being effective in lowering the glucose and glycated hemoglobin levels, some hypoglycemic medications may increase, rather than reduce, the risk of cardiovascular events. 8 – 10 These unexpected findings prompted the reexamination of the regulatory approval processes for new antidiabetic therapies, which had been based primarily on the surrogate measure of glucose lowering with limited clinical-outcomes data. Since . . .
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1509225